Psychedelics.
Nichols DE.
Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR.
JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285.
Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis.
Myran DT, Harrison LD, Pugliese M, Solmi M, Anderson KK, Fiedorowicz JG, Perlman CM, Webber C, Finkelstein Y, Tanuseputro P.
JAMA Psychiatry. 2023 Nov 1;80(11):1169-1174. doi: 10.1001/jamapsychiatry.2023.3582.
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry.
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL.
Am J Psychiatry. 2022 Feb;179(2):98-109. doi: 10.1176/appi.ajp.2021.21030320. Epub 2021 Dec 8.
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.
Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M.
Eur Neuropsychopharmacol. 2023 Nov;76:61-76. doi: 10.1016/j.euroneuro.2023.07.011. Epub 2023 Aug 7.
Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.
Murrie B, Lappin J, Large M, Sara G.
Schizophr Bull. 2020 Apr 10;46(3):505-516. doi: 10.1093/schbul/sbz102.
The History of Psychedelics in Psychiatry.
Nichols DE, Walter H.
Pharmacopsychiatry. 2021 Jul;54(4):151-166. doi: 10.1055/a-1310-3990. Epub 2020 Dec 7.
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W.
Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520.
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.
Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5.
